AngioDynamics ANGO recently announced that the FDA has approved its IDE application to initiate the RELIEF study, which will evaluate the irreversible electroporation (IRE) technology delivered by the ...

The most recent trading session ended with AngioDynamics (ANGO) standing at $5.37, reflecting a -0.74% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...

AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment ...

AngioDynamics prepares to report fiscal fourth-quarter results as attention turns to revenue trends, device demand, valuation, and business progress.

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16. Fourth-quarter sales totaled $70.98 million, beating the ...

AngioDynamics Inc (NASDAQ: ANGO) has reported a second-quarter (Q2) FY24 adjusted EPS loss of $(0.05), compared to the consensus of $(0.07) and EPS income of 1 cent reported a year ago. Q2 sales ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AngioDynamics (ANGO) closed the last trading session at $7.53, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...